Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 3. Biomarkers of biological effect

References

• Adhikari B, Kahende J, Malarcher A, et al. (2008). Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004. MMWR 57:1226–8
   PubMedGoogle Scholar
• Bolinder G, Norén A, de Faire U, Wahren J. (1997). Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. Atherosclerosis 132:95–103
   PubMed Web of Science ®Google Scholar
• Borgerding MF, Bodnar JA, Curtin GM, Swauger JE. (2012). The chemical composition of smokeless tobacco: a survey of products sold in the United States in 2006 and 2007. Regul Toxicol Pharmacol 64:367–87
   PubMed Web of Science ®Google Scholar
• Calapai G, Caputi AP, Mannucci C, et al. (2009). A cross-sectional investigation of biomarkers of risk after a decade of smoking. Inhal Toxicol 21:1138–43
   PubMed Web of Science ®Google Scholar
• Eliasson M, Lundblad D, Hägg E. (1991). Cardiovascular risk factors in young snuff-users and cigarette smokers. J Intern Med 230:17–22
   PubMed Web of Science ®Google Scholar
• Frost-Pineda K, Liang Q, Liu J, et al. (2011). Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. Nicotine Tob Res 13:182–93
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Benowitz NL, Rennard SI, et al. (2006). Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 8:600–22
   PubMed Web of Science ®Google Scholar
• Goto K, Maeda S, Kano Y, Sugiyama T. (1978). Factors involved in differential Giemsa-staining of sister chromatids. Nature 251:156–8
   Google Scholar
• Henley SJ, Connell CJ, Richter P, et al. (2007). Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control 16:22–8
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonization (ICH). (1996). Guidance for industry E6 good clinical practice: consolidated guidance. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf [last accessed 2 Aug 2014]
   Google Scholar
• Kondo T, Hayashi M, Takeshita K, et al. (2004). Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 24:1442–7
   PubMed Web of Science ®Google Scholar
• Latt SA. (1974). Sister chromatid exchanges, indices of human chromosome damage and repair: Detection by fluorescence and induction by mitomycin C. Proc Natl Acad Sci USA 71:3162–6
   PubMed Web of Science ®Google Scholar
• Lee PN. (2011). Summary of the epidemiological evidence relating snus to health. Regul Toxicol Pharmacol 59:197–214
   PubMed Web of Science ®Google Scholar
• Levy DT, Mumford EA, Cummings KM, et al. (2004). The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev 13:2035–42
   PubMed Web of Science ®Google Scholar
• Lowe FJ, Gregg EO, McEwan M. (2009). Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin Chem Lab Med 47:311–20
   PubMed Web of Science ®Google Scholar
• Lowe FJ, Luettich K, Gregg EO. (2013). Lung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspective. Biomarkers 18:183–95
   PubMed Web of Science ®Google Scholar
• Marano KM, Kathman SJ, Jones BA, et al. (2015). Study of cardiovascular disease biomarkers among tobacco consumers. Part 3: evaluation and comparison with the US National Health and Nutrition Examination Survey. Inhal Toxicol 27:167–73
   PubMed Web of Science ®Google Scholar
• Marano KM, Naufal ZS, Borgerding MB, Potts RJ. (2012). Quantitative risk assessment of tobacco-burning and tobacco-heating cigarettes. Rec Adv Tob Sci 38:3–20
   Google Scholar
• Nordskog BK, Brown BG, Marano KM, et al. (2015). Study of cardiovascular disease biomarkers among tobacco consumers, part 2: biomarkers of biological effect. Inhal Toxicol 27:157–66
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Phillips LD, Balfour D, et al. (2014). Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res 20:218–25
   PubMed Web of Science ®Google Scholar
• OECD. (1986). Genetic toxicology: in vitro sister chromatid exchange assay in mammalian cells. Paris: Organization for Economic Co-Operation and Development, 479
   Google Scholar
• Ogden MW, Marano KM, Jones BA, Stiles MF. (2015a). Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: part 1. Study design and methodology. Biomarkers. [Epub ahead of print]. doi: 10.3109/1354750X.2015.1094133
   Google Scholar
• Ogden MW, Marano KM, Jones BA, et al. (2015b). Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: part 2. Biomarkers of exposure. Biomarkers. [Epub ahead of print]. doi: 10.3109/1354750X.2015.1094134
   Google Scholar
• Rennard SI, Daughton D, Fujita J, et al. (1990). Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. Eur Respir J 3:752–9
   PubMed Web of Science ®Google Scholar
• Rennard SI, Umino T, Millatmal T, et al. (2002). Evaluation of subclinical respiratory tract inflammation in heavy smokers who switch to a cigarette-like nicotine delivery device that primarily heats tobacco. Nicotine Tob Res 4:467–76
   PubMedGoogle Scholar
• Roth HD, Roth AB, Liu X. (2005). Health risks of smoking compared to Swedish snus. Inhal Toxicol 17:741–8
   PubMed Web of Science ®Google Scholar
• R.J. Reynolds Tobacco Company (RJRT) and American Snuff Company, LLC (ASC). (2011, July 28). Citizen petition. Available from: http://www.regulations.gov/#!documentDetail;D = FDA-2011-P-0573-0005 [last accessed 2 Aug 2014]
   Google Scholar
• R.J. Reynolds Tobacco Company (RJRT). (2012, August 21). Supplement. Available from: http://www.regulations.gov/#!documentDetail;D = FDA-2011-P-0573-0006 [last accessed 2 Aug 2014]
   Google Scholar
• Stratton K, Shetty P, Wallace R, Bondurant S. (2001). Clearing the smoke: the science base for tobacco harm reduction-executive summary. Tob Control 10:189–95
   PubMed Web of Science ®Google Scholar
• Tonstad S, Cowan JL. (2009). C-reactive protein as a predictor of disease in smokers and former smokers: a review. Int J Clin Pract 63:1634–41
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. (USDHHS). (2010). How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
   Google Scholar
• Wagner BM, Eclipse Expert Panel. (2000). A safer cigarette? A comparative study. A consensus report. Inhal Toxicol 12:1–48
   Google Scholar
• Yan W, Byrd GD, Ogden MW. (2006). Determination of isoprostanes in urine from smokers and never smokers by liquid chromatography tandem mass spectrometry. 54th Annual Conference on Mass Spectrometry and Allied Topics; 2006 May 28–June 1; Seattle, WA
   Google Scholar
• Zeller M, Hatsukami D, Strategic Dialogue on Tobacco Harm Reduction Group. (2009). The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control 18:324–32
   PubMed Web of Science ®Google Scholar